Clinical Trial Update: Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two doses of formoterol fumarate metered-dose inhaler (PT005) versus Foradil Aerolizer in stable COPD was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Foradil Aerolizer (formoterol fumarate inhalation powder)
• Formoterol Fumarate MDI (PT005) (formoterol fumarate inhalation aerosol)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: COPD | Phase 2 | Status: WITHDRAWN